Given that some patients may not adequately respond to single-agent gilteritinib but may benefit from gilteritinib plus chemotherapy, we evaluated the feasibility of combining gilteritinib with AraC/anthracycline or with Aza in preclinical cellular and animal models of FLT3-ITD+ AML. Here, FLT3 is linked to acute myeloid leukemia.